| Literature DB >> 28744906 |
Kenji Akahane1, Kazuma Ojima1, Ayaka Yokoyama1, Toshihiro Inoue1, Sumiyoshi Kiguchi1, Satoshi Tatemichi1, Hiroo Takeda1, Yohsuke Imai1.
Abstract
We examined the effects of combining the rapid insulin secretagogue, mitiglinide, with various oral hypoglycaemic drugs including biguanides, pioglitazone, α-glucosidase inhibitors, and sodium-glucose co-transporter 2 inhibitors in a rat model of type 2 diabetes. The oral glucose tolerance test (OGTT) using glucose, sucrose, or a liquid meal was used to compare the effects of mitiglinide with those of the four oral hypoglycaemic drugs and examine their combined effects on blood glucose levels and insulin secretion in the rat model. The combination of mitiglinide with other oral hypoglycaemic drugs suppressed the plasma glucose levels more than either agent did alone. Furthermore, the combination of these agents decreased insulin secretion more than mitiglinide did alone. These results indicate that mitiglinide is suitable for use in combination with other hypoglycaemic drugs because it inhibits postprandial hyperglycaemia by rapidly stimulating insulin secretion.Entities:
Keywords: SGLT2 inhibitor; biguanide; mitiglinide; pioglitazone; α-glucosidase inhibitor
Mesh:
Substances:
Year: 2017 PMID: 28744906 DOI: 10.1111/1440-1681.12823
Source DB: PubMed Journal: Clin Exp Pharmacol Physiol ISSN: 0305-1870 Impact factor: 2.557